Cardiol Therapeutics Inc
Company Profile
Business description
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
Contact
2265 Upper Middle Road East
Suite 602
OakvilleONL6H 0G5
CANT: +1 289 910-0850
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
18
Stocks News & Analysis
stocks
Telstra earnings: No need to get hysterical over mobile
stocks
Market Minute: RBA cuts rates again, US CPI data released
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,211.30 | 0.80 | -0.01% |
| CAC 40 | 7,923.45 | 53.11 | 0.67% |
| DAX 40 | 24,359.30 | 18.20 | -0.07% |
| Dow JONES (US) | 44,946.12 | 34.86 | 0.08% |
| FTSE 100 | 9,138.90 | 38.34 | -0.42% |
| HKSE | 25,290.01 | 19.94 | 0.08% |
| NASDAQ | 21,622.98 | 87.69 | -0.40% |
| Nikkei 225 | 43,757.84 | 379.53 | 0.87% |
| NZX 50 Index | 12,937.08 | 47.70 | 0.37% |
| S&P 500 | 6,449.80 | 18.74 | -0.29% |
| S&P/ASX 200 | 8,936.60 | 2.00 | -0.02% |
| SSE Composite Index | 3,733.79 | 37.02 | 1.00% |